{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:36:45Z","timestamp":1789475805346,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.semerg.2021.06.008","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T05:59:24Z","timestamp":1629266364000},"page":"472-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Puesta al d\u00eda en distrofia muscular de Duchenne"],"prefix":"10.1016","volume":"47","author":[{"given":"F.","family":"Leiva-Cepas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Monta\u00f1o Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"L\u00f3pez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2021.06.008_bib0170","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/00207454.2018.1430694","article-title":"Duchenne muscular dystrophy: An updated review of common available therapies","volume":"128","author":"Salmaninejad","year":"2018","journal-title":"Int J Neurosci."},{"key":"10.1016\/j.semerg.2021.06.008_bib0175","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: Primary care, emergency management, psychosocial care, and transitions of care across the lifespan","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.semerg.2021.06.008_bib0180","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic developments for Duchenne muscular dystrophy","volume":"15","author":"Verhaart","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"10.1016\/j.semerg.2021.06.008_bib0185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushbyi","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.semerg.2021.06.008_bib0190","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.semerg.2021.06.008_bib0195","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1542\/peds.2018-0333K","article-title":"Primary Care and Emergency Department Management of the patient with duchenne muscular dystrophy","volume":"142","author":"Noritz","year":"2018","journal-title":"Pediatrics."},{"key":"10.1016\/j.semerg.2021.06.008_bib0200","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","article-title":"Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK)","volume":"21","author":"Moat","year":"2013","journal-title":"Eur J Hum Genet."},{"key":"10.1016\/j.semerg.2021.06.008_bib0205","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","article-title":"Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011","volume":"56","author":"Kieny","year":"2013","journal-title":"Ann Phys Rehabil Med."},{"key":"10.1016\/j.semerg.2021.06.008_bib0210","first-page":"121","article-title":"Improvement of survival in Duchenne muscular dystrophy: Retrospective analysis of 835 patients","volume":"31","author":"Passamano","year":"2012","journal-title":"Acta Myol."},{"key":"10.1016\/j.semerg.2021.06.008_bib0215","first-page":"117","article-title":"Survival in Duchenne muscular dystrophy","volume":"31","author":"Rall","year":"2012","journal-title":"Acta Myol."},{"key":"10.1016\/j.semerg.2021.06.008_bib0220","doi-asserted-by":"crossref","first-page":"18168","DOI":"10.3390\/molecules201018168","article-title":"Duchenne muscular dystrophy: From diagnosis to therapy","volume":"20","author":"Sofia Falzarano","year":"2015","journal-title":"Molecules."},{"key":"10.1016\/j.semerg.2021.06.008_bib0225","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.nrl.2018.01.001","article-title":"Consenso para el diagn\u00f3stico, tratamiento y seguimiento del paciente con distrofia muscular de Duchenne","volume":"34","author":"Nascimento Osorio","year":"2019","journal-title":"Neurolog\u00eda."},{"key":"10.1016\/j.semerg.2021.06.008_bib0230","first-page":"47","article-title":"Distrofia muscular de Duchenne","volume":"12","author":"Camacho","year":"2014","journal-title":"An Pediatr Contin."},{"key":"10.1016\/j.semerg.2021.06.008_bib0235","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.26736","article-title":"Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials","volume":"61","author":"McDonald","year":"2020","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.semerg.2021.06.008_bib0240","doi-asserted-by":"crossref","first-page":"928385","DOI":"10.1155\/2015\/928385","article-title":"Optimizing bone health in Duchenne muscular dystrophy","volume":"2015","author":"Buckner","year":"2015","journal-title":"Int J Endocrinol."},{"key":"10.1016\/j.semerg.2021.06.008_bib0245","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000006950","article-title":"Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial","volume":"92","author":"Taylor","year":"2019","journal-title":"Neurology."},{"issue":"Suppl 2","key":"10.1016\/j.semerg.2021.06.008_bib0250","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1542\/peds.2018-0333G","article-title":"Nutritional and gastrointestinal management of the patient with Duchenne muscular dystrophy","volume":"142","author":"Brumbaugh","year":"2018","journal-title":"Pediatrics."},{"key":"10.1016\/j.semerg.2021.06.008_bib0255","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: Respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.semerg.2021.06.008_bib0260","series-title":"Una gu\u00eda para maestros sobre las enfermedades neuromusculares","author":"Hall","year":"2006"},{"key":"10.1016\/j.semerg.2021.06.008_bib0265","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1542\/peds.2010-3177","article-title":"US Preventive Services Task Force Vision screening for children 1 to 5 years of age: US Preventive Services Task Force recommendation statement","volume":"127","author":"Calonge","year":"2011","journal-title":"Pediatrics."},{"key":"10.1016\/j.semerg.2021.06.008_bib0270","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrm.2016.7","article-title":"Molecular circuitry of stem cell fate in skeletal muscle regeneration, ageing and disease","volume":"17","author":"Almada","year":"2016","journal-title":"Nat Rev Mol Cell Biol."},{"key":"10.1016\/j.semerg.2021.06.008_bib0275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.omtn.2016.11.009","article-title":"Systemic antisense therapeutics for dystrophin and myostatin exon splice modulation improve muscle pathology of adult mdx mice","volume":"6","author":"Lu-Nguyen","year":"2017","journal-title":"Mol Ther Nucleic Acids."},{"key":"10.1016\/j.semerg.2021.06.008_bib0280","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2217\/cer-2020-0095","article-title":"Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy","volume":"9","author":"Campbell","year":"2020","journal-title":"J Comp Eff Res."},{"key":"10.1016\/j.semerg.2021.06.008_bib0285","doi-asserted-by":"crossref","first-page":"e15858","DOI":"10.1097\/MD.0000000000015858","article-title":"Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy","volume":"98","author":"Alfano","year":"2019","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.semerg.2021.06.008_bib0290","first-page":"43","article-title":"Read-through approach for stop mutations in Duchenne muscular dystrophy. An update","volume":"40","author":"Politano","year":"2021","journal-title":"Acta Myol."},{"key":"10.1016\/j.semerg.2021.06.008_bib0295","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ppul.23547","article-title":"Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy","volume":"52","author":"Buyse","year":"2017","journal-title":"Pediatr Pulmonol."},{"key":"10.1016\/j.semerg.2021.06.008_bib0300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.nmd.2019.10.008","article-title":"Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy","volume":"30","author":"Servais","year":"2020","journal-title":"Neuromuscular Disorders."},{"key":"10.1016\/j.semerg.2021.06.008_bib0305","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13023-019-1066-9","article-title":"Effect and safety of treatment with ACE-inhibitor Enalapril and \u03b2-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy \u2014a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Dittrich","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.semerg.2021.06.008_bib0310","first-page":"77","article-title":"Avances en el tratamiento de la distrofia de Duchenne","volume":"79","author":"Ortez","year":"2019","journal-title":"Medicina (B Aires)."},{"key":"10.1016\/j.semerg.2021.06.008_bib0315","doi-asserted-by":"crossref","first-page":"113086","DOI":"10.1016\/j.expneurol.2019.113086","article-title":"Stem cell-based therapies for Duchenne muscular dystrophy","volume":"323","author":"Sun","year":"2020","journal-title":"Exp Neurol."},{"key":"10.1016\/j.semerg.2021.06.008_bib0320","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/cpdd.642","article-title":"A phase 1b trial to assess the pharmacokinetics of ezutromid in pediatric Duchenne muscular dystrophy patients on a balanced diet","volume":"8","author":"Muntoni","year":"2019","journal-title":"Clin Pharmacol Drug Dev."},{"key":"10.1016\/j.semerg.2021.06.008_bib0325","doi-asserted-by":"crossref","first-page":"7880","DOI":"10.1021\/acs.jmedchem.0c00807","article-title":"2-arylbenzo[d]oxazole phosphinate esters as second-generation modulators of utrophin for the treatment of Duchenne muscular dystrophy","volume":"63","author":"Babbs","year":"2020","journal-title":"J Med Chem."},{"key":"10.1016\/j.semerg.2021.06.008_bib0330","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3892\/etm.2021.9875","article-title":"Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)","volume":"21","author":"Zhang","year":"2021","journal-title":"Exp Ther Med."}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359321002136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359321002136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:41:35Z","timestamp":1761108095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359321002136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1138359321002136"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2021.06.008","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Puesta al d\u00eda en distrofia muscular de Duchenne","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2021.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}